World-renowned lung cancer researcher
2026 Award Recipient
![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Posts
🚀Great talk by @sebrmedina at #ASCO26 | ST-DoxPCa is an AI-driven biomarker that is transforming metastatic hormone-sensitive prostate cancer treatment by predicting response to docetaxel | Abstract 5002 | #CHAARTED #3805 @GeorgiaTech @EmoryNews
Today til Noon #ASO26: Talk w Megan Baumgart about opening ACHIEVE /EA5221 | Hall A | Board 456B | Does chemotherapy improve outcomes for older pts w advanced NSCLC compared to immunotherapy alone? An important geriatric oncology trial! Miss the session? https://blog-ecog-acrin.org/trial-spotlight-megan-baumgart-highlights-the-achieve-trial-for-patients-aged-70-plus-with-advanced-non-small-cell-lung-cancer/
Today Until Noon #ASO26: Talk w @MonikaJoshimd @PennState about opening EA8231 | Hall A | Board 19 | This study explores pembrolizumab + targeted therapy w sacituzumab govitecan in anti-PD(L)1-resistant advanced urothelial cancer. Miss the session? https://blog-ecog-acrin.org/now-enrolling-ea8231-study-for-patients-with-bladder-cancer-that-has-progressed-following-treatment/
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
33
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, we are a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
